Cannabis Abstinence and Neurocognitive Assessment in Adolescence (CANAA)

University Hospital Pilsen

Status

Enrolling

Conditions

Cannabis Dependence

Harmful Use

Cognitive Assessment

Treatments

Diagnostic Test: Neurocognitive assessment

Diagnostic Test: Urine toxicological assessment

Study type

Observational

Funder types

Other

Identifiers

NCT07160153

CANAA

Details and patient eligibility

About

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Full description

Evaluate the development of cognitive functions following attainment of abstinence in a group of adolescents with cannabis dependence or harmful cannabis use. Abstinence is confirmed by toxicological testing.

Enrollment

29 estimated patients

Sex

All

Ages

15 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Exclusion criteria

psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.